Lineage Cell Therapeutics, Inc. (LCTX) Reports $4.2M Q3 Net Income; Acquires NeuroAirmid
Lineage reported Q3 2026 net income of $4.2M versus a $29.8M net loss in Q3 2025, primarily due to non-cash warrant remeasurement. It closed the NeuroAirmid acquisition, adding clinical-stage HUNT1 to its pipeline.Material DetailsContext by AI AnalystThe acquisition broadens Lineage’s clinical-stag…